

Appendix B

Patent  
Attorney Docket # NREL 99-45



**CELLOBIOHYDROLASE I GENE AND IMPROVED VARIANTS**

**By**

**William S. Adney  
Stephen R. Decker  
Suzanne McCarter  
John O. Baker  
Rafael Nieves  
Michael E. Himmel  
Todd B. Vinzant**

**CELLOBIOHYDROLASE I GENE AND IMPROVED VARIANTS**

The United States Government has rights in this invention under contract number DE-AC36-99G0-10337 between the United States Department of Energy and the National Renewable Energy Laboratory, a division of the Midwest Research Institute.

The present application claims priority to PCT Application PCT/US00/19007 filed July 13, 2000, which is hereby incorporated by reference. PCT/US00/19007 claims priority to U.S. Provision Application 60/143,711 filed July 13, 1999.

**Field of the Invention**~~**Technical Field.**~~

This invention relates to 1,4-  $\beta$ -cellobiohydrolases or exoglucanases. More specifically, it relates to the *Trichoderma reesei* cellobiohydrolase I gene, the creation of reduced glycosylation variants of the expressed CBH I protein to enable the expression of active enzyme in heterologous hosts, and to the creation of new thermal stable variants of the enzyme that instill higher thermal tolerance on the protein and improved performance.

**Background of the Invention**~~**Art.**~~

The surface chemistry of acid pretreated-biomass, used in ethanol production, is different from that found in plant tissues, naturally digested by fungal cellulase enzymes, in two important ways: (1) pretreatment heats the substrate past the phase-transition temperature of lignin; and (2) pretreated biomass contains less acetylated hemicellulose. Thus, it is believed, that the cellulose fibers of pretreated-biomass are coated with displaced and modified lignin. This alteration results in a non-specific binding of the protein with the biomass, which impedes enzymatic activity. Moreover, where the pretreated biomass is a hardwood-pulp it contains a weak net-negatively charged surface, which is not observed in native wood. Therefore, for the efficient production of ethanol from a pretreated biomass such as corn stover, wood or other biomass it is desirable to enhance the catalytic activity of glycosyl hydrolases specifically the cellobiohydrolases.

*Trichoderma reesei* CBH I (SEQ ID NO: 5) is a mesophilic cellulase which plays a major role in the hydrolysis of cellulose. An artificial ternary cellulase system consisting of a 90:10:2 mixture of *T. reesei* CBH I, *Acidothermus cellulolyticus* EI, and *Aspergillus niger*  $\beta$ -D-glucosidase is capable of releasing as much reducing sugar from pretreated yellow poplar as the

native *T. reesei* system after 120 h. This result is encouraging for the ultimate success of engineered cellulase systems, because this artificial enzyme system was tested at 50°C, a temperature far below that considered optimal for EI, in order to spare the more heat labile enzymes CBH I and  $\beta$ -D-glucosidase. To increase the efficiency of such artificial enzyme systems it is desirable to engineer new *T. reesei* CBH I variant enzymes capable of active expression in heterologous hosts. The use of the heterologous host *Aspergillus awamori*, could provide an excellent capacity for synthesis and secretion of *T. reesei* CBH I because of its ability to correctly fold and post-translationally modify proteins of eukaryotic origin. Moreover, *A. awamori* is believed to be an excellent test-bed for *Trichoderma* coding sequences and resolves some of the problems associated with site directed mutagenesis and genetic engineering in *Trichoderma*.

In consideration of the foregoing, it is therefore desirable to provide variant cellulase enzymes having enzymatic activity when expressed in a heterologous host, and to provide variant cellulase enzymes that have improve thermal tolerance over the native as produced by *Trichoderma reesei*.

#### **Disclosure Summary of the Invention.**

It is a general object of the present invention to provide variant cellulase enzymes having enzymatic activity when expressed in a heterologous host, such as a filamentous fungi or yeast.

Another object of the invention is to provide a variant exoglucanases characterized by a reduction in glycosylation when expressed in a heterologous host.

Another object of the invention is to provide an active cellobiohydrolase enzyme capable of expression in heterologous fungi ~~or~~ including yeast.

Another object of the invention is to provide improved thermal tolerant variants of the cellobiohydrolase enzyme capable of functioning at increased process temperatures.

It is yet another object of the invention to provide a method for reducing the glycosylation of a cellobiohydrolase enzyme for expression in a heterologous host.

The foregoing specific objects and advantages of the invention are illustrative of those which can be achieved by the present invention and are not intended to be exhaustive or limiting of the possible advantages which can be realized. Thus, those and other objects and advantages

of the invention will be apparent from the description herein or can be learned from practicing the invention, both as embodied herein or as modified in view of any variations which may be apparent to those skilled in the art.

Briefly, the invention provides a method for making an active cellobiohydrolase in a heterologous host, the method comprising reducing glycosylation of the cellobiohydrolase, reducing glycosylation further comprising reducing an N-glycosylation site amino acid residue with a non-glycosyl accepting amino acid residue. The invention further provides a cellobiohydrolase, comprising the reduced glycosylation variant cellobiose enzymes CBHI-N45A; CBHI-N270A; or CBHI-N384A, or any combination thereof.

**Best Mode for Carrying out Detailed Description of the Invention.**

Unless specifically defined otherwise, all technical or scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are now described.

The terms "native" and "wild-type" are used interchangeably throughout this disclosure to indicate the origin of the molecule as it occurs in nature.

A method for reducing the glycosylation of an expressed *Trichoderma reesei* CBHI protein by site-directed mutagenesis ("SDM") is disclosed. The method includes replacing an N-glycosylation site amino acid residue, such as asparagines 45, 270, and/or 384 (referenced herein as CBHI-N45A, CBHI-N270A and CBHI-N384A, respectively), with a non-glycosyl accepting amino acid residue, such as is alanine. Various mutagenesis kits for SDM are available to those skilled in the art and the methods for SDM are well known. The description below discloses a procedure for making and using CBHI variants: CBHI-N45A (SEQ ID NO: 6); CBHI-N270A (SEQ ID NO: 7); and CBHI-N384A (SEQ ID NO: 8). The examples below demonstrate the expression of active CBHI in the heterologous fungus *Aspergillus awaniori*.

Variants of CBH I embodiments include mutations that provide for improved end product inhibition and for thermal tolerance.

**Brief Description of the Figures.**

Figure 1. Coding sequence ~~of for~~ the *cbh 1* gene (SEQ ID NO: 4). ~~Small~~ Lower case letters represent the signal sequence, ~~large~~ upper case letters the catalytic domain, bolded italics the linker region, and ~~large~~ upper case underlined the cellulose-binding domain.

Figure 2. SDS-PAGE Western blot with anti-CBH I antibody showing the reduction on molecular weight of rCBH I expression clones as a function of introduction of N to A modifications.

Figure 3. Plasmid map for the fungal expression vector pPFE2/CBH I.

Figure 4. ~~Coding~~ Nucleotide sequence, SEQ ID NO: 1—19, 5'-CCTCCCGGCGGAAACCCGCCTGGCACCACCACCACCCGCCGCCCA-3', coding for the linker region, PPGGNPPGTTTTRRP (SEQ ID NO: 2), of the CBH I protein, ~~*cbh 1* gene~~, SEQ ID NO: 4, showing additional proline residues ~~nucleotides~~ that effect conformation of the linker region in the protein structure.

**Example 1. Acquisition of the CBH I Encoding Sequence.**

Acquisition of the gene was done by either cDNA cloning or by PCR of the gene from genomic DNA. CBH I cDNA was isolated from a *T. reesei* strain RUT C-30 cDNA library constructed using a PCR-generated probe based on published CBH I gene sequences (Shoemaker, et al., 1983). The cDNA's were cloned (using the Zap Express cDNA kit from Stratagene; cat. #200403) into the XhoI and EcoRI site(s) of the supplied, pre-cut lambda arms. An XhoI site was added to the 3' end of the cDNA during cDNA synthesis, and sticky-ended RE linkers were added to both ends. After XhoI digestion, one end has an XhoI overhang, and the other (5' end) has an Eco RI overhang. The insert can be removed from this clone as an approximately 1.7 kb fragment using SalI or SpeI plus XhoI in a double digest. There are two Eco RI, one Barn HI, 3 SacI and one HindIII sites in the coding sequence of the cDNA itself. The plasmid corresponding to this clone was excised *in vivo* from the original lambda clone, and corresponds to pB210-5A. Thus, the cDNA is inserted in parallel with a Lac promoter in the pBK-CMV parent vector. Strain pB210-5A grows on LB + kanamycin (50  $\mu$ g/mL).

Acquisition of the *cbh 1* gene was also achieved by PCR of genomic DNA. With this approach the fungal chromosomal DNA from *T. reesei* strain Rut C-30 was prepared by grinding

the fungal hyphae in liquid nitrogen using a mortar and pestle to a fine powder. The genomic DNA was then extracted from the cell debris using a Qiagen DNAeasy Plant Mini kit. Amplification of the DNA fragment that encodes for the *cbh 1* gene, including introns, was performed using polymerase chain reaction (PCR) with specific primers for the *T. reesei cbh 1* gene. The primers 5'-AGAGAGTCTAGACACGGAGCTTACAGGC-3' (SEQ ID NO: 9) that introduces a Xba I site and the primer 5'-AAAGAAGCGCGGCCGCGCCTGCACTCTCCAATCGG-3' (SEQ ID NO: 97) that introduces a unique Not I site were used to allowing cloning into the pPFE *Aspergillus/E. coli* shuttle vectors that are described below. The amplified PCR product was then gel purified and cloned directly into the vectors.

**Example 2. Production of Active Recombinant CBH I (rCBH I) in *Aspergillus awamori*. Construction of the Fungal Expression Vectors pPFE-1/CBH I[1] and pPFE-2/CBH I[1].**

The coding sequence for *T. reesei* CBH I was successfully inserted and expressed in *Aspergillus awamori* using the fungal expression vector pPFE2 (and pPFE1). Vectors pPFE1 and pPFE2 are *E. coli* - *Aspergillus* shuttle vectors, and contain elements required for maintenance in both hosts. Both pPFE-1 and pPFE-2 vectors direct the expression of a fusion protein with a portion of the glucoamylase gene fused to the gene of interest. The pPFE1 vector contains a region of the glucoamylase gene, with expression under the control of the *A. awamori* glucoamylase promoter. The protein of interest is expressed as a fusion protein with the secretion signal peptide and 498 amino acids of the catalytic domain of the glucoamylase protein. The majority of the work presented here was done using the pPFE2 expression vector, which was chosen because of its smaller size, simplifying the PCR mutation strategy by reducing extension time.

The major features of the pPFE2-CBH1 construct are shown in Figure 3. With both the pPFE1/CBH1 and the pPFE2/CBH1 vectors, the sequence immediately upstream of the Not I site encodes a LysArg dipeptide. A host KEX-2 like protease recognizes this dipeptide sequence during the secretion process, and the fusion peptide is cleaved, removing the glucoamylase secretion signal peptide or the longer catalytic domain of glucoamylase in the case of pPFE1. In this way, the recombinant CBH I protein experiences an "efficient ride" through the *A. awamori* secretion system and is expressed with the native N-terminal protein. The net result is that the recombinant CBH I is processed so that it can accumulate in the medium without its

glucoamylase secretion signal fusion partner. The vector contains the *Streptoalloteichus hindustanus* phleomycin resistance gene, under the control of the *A. niger*  $\beta$ -tubulin promoter, for positive selection of *Aspergillus* transformants. The pPFE/CBH1 vector also contains a  $\beta$ -lactamase gene for positive selection using ampicillin in *E. coli*, and also contains the *A. niger* trpC terminator. The insertion of the CBH I coding sequence into the pPFE vectors was accomplished using two methods. Vector DNA was first produced in 500 mL cultures of *E. coli* XL1 Blue and the plasmids purified using Promega maxi-preps DNA purification kits.

#### **Approach 1: Blunt-Xba I fragment generation.**

1. Oligonucleotides were designed to give a blunt end on the 5' end and an engineered Xba I site on the 3' end of the PCR fragment.
2. The full-length coding sequence for CBH I was obtained by PCR using Pfu DNA polymerase and using the cDNA construct pB510-2a as the template. Pfu DNA polymerase generates blunt-ended PCR products exclusively.
3. The pPFE vectors were digested using NotI and confirmed by agarose gel electrophoresis. The NotI overhang was then digested using Mung Bean nuclease. The DNA was purified and the vector and CBH I PCR fragment digested using XbaI.
4. The vector and PCR product were then ligated using T4 DNA ligase and the DNA used to transform *E. coli* XL-1 Blue and *E. coli* DH5 $\alpha$  using electroporation.

#### **Approach 2: NotI-XbaI fragment approach.**

1. Oligonucleotides were designed to give a Not I site on the 5' end, and an engineered Xba I site on the 3' end of the PCR fragment.
2. The full-length coding sequence for CBH I was obtained by PCR using Pfu DNA polymerase and using the cDNA construct pB510-2a as the template.
3. The pPFE vectors and the PCR product were digested using Not I and Xba I
4. The CBH I PCR product was directionally cloned into the pPFE2 vector using T4 DNA ligase and transformed into *E. coli* XL-1 Blue.

5. The insertion of the CBH I coding sequence into the pPFE2 vector was confirmed using PCR, restriction digest analysis, and DNA sequencing through the insertion sites. The entire coding sequence of the insert was also confirmed by DNA sequencing.

The constructs produced using these two methods was then used to transform *A. awamori* and to express rCBH I, as confirmed by western blot analysis of culture supernatant. The rCBH I expressed in *A. awamori* tends to be over glycosylated as evidenced by the higher molecular weight observed on western blot analysis. Over glycosylation of CBH I by *A. awamori* was confirmed by digestion of the recombinant protein with endoglycosidases. Following endoglycosidase H and F digestion, the higher molecular weight form of the protein collapses to a molecular weight similar to native CBH I.

**Example 3. Method for producing PCR site directed mutations for glycosylation removal and improved thermalstability.**

The QuickChange™ Site Directed Mutagenesis kit (StrataGene, San Diego, CA) was used to generate mutants with targeted amino acid substitutions. To introduce these specific amino acid substitutions, mutagenic primers (between 25 and 45 bases in length) were designed to contain the desired mutation that would result in the targeted amino acid substitution. Pfu DNA polymerase was then used to amplify both strands of the double-stranded vector, which contained the CBH I insertion sequence, with the resultant inclusion of the desired mutation from the synthetic oligonucleotides. Following temperature cycling, the product was treated with the exonuclease Dpn I to digest the parental methylated DNA template and the PCR product was used to transform Epicurian Coli XL1-Blue supercompetent cells.

The vector pPFE2/CBHI requires a relatively long PCR reaction (8.2 kB) to make site-specific changes using the Stratagene Quik Change protocol. The PCR reaction was optimized as follows using a GeneAmp PCR System 2400, Perkin Elmer Corporation. The reaction mixture contained 50 ng of template DNA, 125 ng each of the sense and antisense mutagenic primers, 5 mL of Stratagene 10X cloned *Pfu* buffer, 200 µM of each: dNTP, 5 mM MgCl<sub>2</sub> (total final concentration of MgCl<sub>2</sub> is 7 mM); and 2.5 U *Pfu* Turbo DNA polymerase. The PCR reaction was carried out for 30 cycles, each consisting of one minute denaturation at 96°C, 1 minute annealing at 69°C and a final extension for 10 min at 75°C, followed by a hold at 4°C. Agarose gel

electrophoresis, ethidium bromide staining, and visualization under UV transillumination were used to confirm the presence of a PCR product.

PCR products were digested with the restriction enzyme Dpn1, to degrade un-mutagenized parental DNA, and transformed into *E. coli* (Stratagene Epicurian Coli Supercompetent XL-1 Cells). Ampicillin resistant colonies were picked from LB-amp100 plates and mutations were confirmed by DNA sequencing.

Template DNA from *E. coli* XL1-blue cells transformed with Dpn1 treated mutagenized DNA was prepared for sequencing using the QIAprep-spin plasmid purification mini-prep procedure (Qiagen, Inc.). The transformed XL1-blue cells were grown overnight in 5 mL of LB broth with 100 µg/mL ampicillin selection. Cells were removed by centrifugation and the plasmid isolated using the protocol outlined in the QIAprep-spin handbook. The concentration of the template DNA was adjusted to 0.25 µg/µL and shipped along with sequencing oligonucleotides to the DNA Sequencing Facility at Iowa State University.

After the mutation was confirmed by DNA sequence alignment comparisons using the software package OMIGA, and the DNA was prepared for transformation of *A. awamori*. The transformed *E. coli* XL1/blue cells were grown overnight on LB plates with 100 µg/mL ampicillin at 37°C. A single colony was then used to inoculate a 1 L baffled Erlenmeyer flask that contained 500 mL of LB broth and 100 µg/mL ampicillin. The culture was allowed to grow for 16 to 20 hours at 37°C with 250 rpm shaking in a NBS reciprocating shaking incubator. The cells were harvested and the plasmid DNA purified using a Promega maxi-prep purification kit. The purified maxi-prep DNA was subsequently used to transform *A. awamori* spheroplasts using the method described below.

**Transformation of *Aspergillus awamori* with *Trichoderma reesei* CBH I coding sequence. Generating Fungal Spheroplasts.**

*A. awamori* spheroplasts were generated from two-day-old cultures of mycelia pellets. A heavy spore suspension was inoculated into 50 mL of CM broth (5.0 g/L yeast extract; 5.0 g/L tryptone; 10 g/L glucose; 50 mL/L 20X Clutterbuck's salts, pH 7.5 (adjusted by addition of 2.0N NaOH)) and grown at 225 rpm and 28°C in a baffled 250 mL Erlenmeyer flask. The mycelia were collected by filtration through Miracloth and washed with ~200 mL KCM (0.7M KCl; 10mM MOPS pH 5.8). The washed mycelia were transferred to 50 mL, of KCM + 500 mg

Novazym 234 in a 50-mL unbaffled flask and incubated O/N at 80rpm and 30°C. After digestion, the remaining mycelia was removed by filtration through Miracloth and the spheroplasts were collected in 50 mL disposable tubes and pelleted at 2500 x g in a swinging bucket rotor for 15 minutes. The supernatant was discarded and the spheroplasts gently resuspended in 20 mL 0.7M KCl by titration with a 25-mL disposable pipet. The spheroplasts were pelleted and washed again, then resuspended in 10 mL KC (0.7M KCl + 50mM CaCl<sub>2</sub>). After being pelleted, the spheroplasts were resuspended into 1.0 mL of KC.

Transformation was carried out using 50 µL of spheroplasts + 5 µL DNA (pPFE1 or pPFE2 ~200 µg/mL) + 12.5 µL PCM (40% PEG8000 + 50mM CaCl<sub>2</sub> + 10 mM MOPS pH 5.8). After incubation for 60 mins on ice, 0.5mL PCM was added and the mixture was incubated for 45 mins at room temperature. One milliliter of KCl was added and 370 µL of the mix was added to 10 mL of molten CMK (CM + 2% agar + 0.7M KCl) top agar at 55°C. This mixture was immediately poured onto a 15mL CM170 plate (CM + 2% agar + 170µg/mL Zeocin). Negative transformation controls substituted sterile dH<sub>2</sub>O for DNA. Plating the transformation mix onto CM plates without Zeocin performed positive spheroplast regeneration controls. The poured plates were incubated at 28°C in the dark for 2-7 days.

**Transformation of *Aspergillus awamori* with native and modified CBH I coding sequence.**

*Aspergillus awamori* spore stocks were stored at -70°C in 20% glycerol, 10% lactose. After thawing, 200 µL of spores were inoculated into 50 mL CM broth in each of eight-baffled 250 mL Erlenmeyer flask. The cultures were grown at 28°C, 225 rpm for 48 h. The mycelial balls were removed by filtration with sterile Miracloth (Calbiochem, San Diego, CA) and washed thoroughly with sterile KCM. Approximately 10 g of washed mycelia were transferred to 50 mL KCM + 250 mg Novozym234 in a 250 mL baffled Erlenmeyer flask. The digestion mixture was incubated at 30°C, 80 rpm for 1-2 h and filtered through Miracloth into 50 mL conical centrifuge tubes. The spheroplasts were pelleted at 2000xg for 15 min and resuspended in 0.7M KCl by gentle titration with a 25 mL pipette. This was repeated once. After a third pelleting, the spheroplasts were resuspended in 10 mL KC, pelleted and resuspended in 0.5 mL KC using a wide-bore pipet tip. The washed spheroplasts were transformed by adding 12.5 µL PCM and 5 µL DNA (~0.5 µg/µL) to 50 µL of spheroplasts in sterile 1.5 mL Eppendorf tubes. After incubation on ice for 45 minutes, 0.5 mL of room temperature PCM was added to the

transformation mixture and was mixed by titration with a wide bore pipet tip. The mixture was incubated at room temperature for 45 minutes. One milliliter of KC was added and mixed. The mixture was allocated between four tubes of CM top agar at 55°C, which were each poured over a 15 mL CM170 plate. The plates were incubated at 28°C for 2-3 days. Subsurface colonies were partially picked with a sterile wide bore pipet tip, exposing the remaining part of the colony to air and promoting rapid sporulation. After sporulation, spores were streaked onto several successive CM100 or CM300 plates. After a monoculture was established, heavily sporulated plates were flooded with sterile spore suspension medium (20% glycerol, 10% lactose), the spores were suspended and aliquots were frozen at -70°C. Working spore stocks were stored on CM slants in screw cap tubes at 4°C. Protein production was confirmed and followed by western blot using anti-CBH I monoclonal antibodies and the Novex Western Breeze anti-mouse chromogenic detection kit (Novex, San Diego, CA). Extracting genomic DNA using the YeaStar Genomic DNA Kit (Zymo Research, Orange, CA) and carrying out PCR with *pfu*-turbo DNA polymerase (Stratagene, La Jolla) and *cbh 1* primers confirmed insertion of the gene.

#### **Production and purification of native rCBH I enzyme from *Aspergillus awamori*.**

For enzyme production, spores were inoculated into 50 mL CM basal starch medium, pH 7.0, and grown at 32°C, 225 rpm in 250 mL baffled flasks. The cultures were transferred to 1.0 L of basal starch medium in 2800 mL Fernbach flasks and grown under similar conditions. For large-scale enzyme production (>1 mg), these cultures were transferred to 10 L basal starch medium in a New Brunswick BioFlo3000 fermenter (10-L working volume) maintained at 20% DO, pH 7.0, 25°C, and 300 rpm. The fermentation was harvested by filtration through Miracloth after 2-3 days of growth.

After further clarification by glass fiber filtration, the rCBH I protein was purified by passing the fermentation broth over four CBinD900 cartridge columns (Novagen, Madison, WI) connected in parallel using a Pharmacia FPLC System loading at 1.0 mL/min (Amersham Pharmacia Biotech, Inc., Piscataway, NJ). The cartridges were equilibrated in 20 mM Bis-Tris pH 6.5 prior to loading and washed with the same buffer after loading. The bound rCBH I was then eluted with 100% ethylene glycol (3 mL/column) using a syringe. Alternatively, the supernatant was passed over a para-aminophenyl  $\beta$ -D-cellobioside affinity column, washed with 100 mM acetate buffer, pH 5.0, 1mM gluconolactone and eluted in the same buffer containing

## Appendix B

Patent  
Attorney Docket # NREL 99-45

10mM cellobiose. In either method, the eluted rCBH I was concentrated in Millipore Ultrafree-15 spin concentrator with a 10kDa Biomax membrane to <2.0 mL and loaded onto a Pharmacia SuperDex200 16/60 size-exclusion column. The mobile phase was 20 mM sodium acetate, 100 mM sodium chloride, and 0.02% sodium azide, pH 5.0 running at 1.0 mL/min. The eluted protein was concentrated and stored at 4°C. Protein concentrations were determined for each mutant based upon absorbance at 280 nm and calculated from the extinction coefficient and molecular weight for each individual protein as determined by primary amino acid sequence using the ProtParam tool on the ExPASy website (<http://www.expasy.ch/tools/protparam.html>).

### Clutterbuck's Salts (20X)

Na <sub>2</sub> NO <sub>3</sub>	120.0 g
KCl	10.4
MgSO <sub>4</sub> •7H <sub>2</sub> O	10.4
KH <sub>2</sub> PO <sub>4</sub>	30.4

### CM-

Yeast Extract-	5 g/L
Tryptone-	5 g/L
Glucose-	10 g/L
Clutterbuck's Salts-	50 mL
Add above to 900 mL dH <sub>2</sub> O, pH to 7.5, bring to 1000 mL	

### CM Agar-CM + 20g/L Agar

### CMK-CM Agar + 0.7M KCl

### CM100-CM + 100 µg/mL Zeocin (Invitrogen, Carlsbad, CA)

### CM170-CM + 170 µg/mL Zeocin, 15mL/plate

### KCl-0.7M KCl

### KC-0.7M KCl + 50 mM CaCl<sub>2</sub>

### KCM- 0.7M KCl + 10mM MOPS, pH 5.8

### PCM-40% PEG 8000, 50 mM CaCl<sub>2</sub>, 10 mM MOPS pH 5.8 (mix 4 mL 50% PEG + 0.5 mL 500 mM CaCl<sub>2</sub> stock + 0.5 mL 100 mM MOPS stock)

### Basal Starch Medium-

Casein Hydrolysate, Enzymatic	5 g/L
NH <sub>4</sub> CL	5 g/L
Yeast Extract	10 g/L
Tryptone	10 g/L

MgSO <sub>4</sub> *7H <sub>2</sub> O	2 g/L
Soluble Starch	50 g/L
Buffer (Bis-Tris-Propane)	50 mM
pH to 7.0 with NaOH	

**Example 4. Production of Reduced Glycosylation rCBH I: Sites N270A; N45A; and N384A.**

rCHI/pPFE2 has been optimized using site-directed mutagenesis to achieve expression of native molecular weight CBH I in *A. awamori* by the following ways. The QuickChange SDM kit (Stratagene, San Diego, CA) was used to make point mutations, switch amino acids, and delete or insert amino acids in the native *cbh 1* gene sequence. The Quick Change SDM technique was performed using thermotolerant *Pfu* DNA polymerase, which replicates both plasmid strands with high fidelity and without displacing the mutant oligonucleotide primers. The procedure used the polymerase chain reaction (PCR) to modify the cloned *cbh 1* DNA. The basic procedure used a supercoiled double stranded DNA (dsDNA) vector, with the *cbh 1* gene insert, and two synthetic oligonucleotide primers containing a desired mutation. The oligonucleotide primers, each complimentary to opposite strands of the vector, extend during temperature cycling by means of the polymerase. On incorporation of the primers, a mutated plasmid containing the desired nucleotide substitutions was generated. Following temperature cycling, the PCR product was treated with a DpnI restriction enzyme. DpnI is specific for methylated and hemi-methylated DNA and thus digests the unmutated parental DNA template, selecting for the mutation-containing, newly synthesized DNA. The nicked vector DNA, containing the desired mutations, was then transformed into *E. coli*. The small amount of template DNA required to perform this reaction, and the high fidelity of the *Pfu* DNA polymerase contribute to the high mutation efficiency and minimizes the potential for the introduction of random mutations. Three glycosylation-site amino acids on the pro surface were targeted for substitution of an alanine (A) residue in place of asparagines (N). Single site substitutions were successfully completed in the *cbh 1* coding sequence at sites N45, N270, and N384, of Seq. ID NO: 4 by site-directed mutagenesis, and confirmed by DNA sequencing.

Double and triple combinations of this substitution have also been completed in the *cbh 1* coding sequence at sites N45, N270, and N384 by site directed mutagenesis and confirmed by DNA sequencing. These double and triple site constructs also yield rCBH I enzymes with reduced glycosylation and, presumably, native activity.

Table 1.

Construct	Host	MW (kDa)	$K_m$ $\mu\text{mol pNPL}$	$V_{\text{max}}$ $\mu\text{mol pNP/min/mg protein}$
<i>T. reesei</i>	None	57.8	1.94	0.746
rCBHI wt cDNA	<i>A. awamori</i>	63.3	2.14	0.668
rCBHI wt genomic	<i>A. awamori</i>	63.3	--	--
rCBHI N270A	<i>A. awamori</i>	61.7	2.25	0.489
rCBHI N384A	<i>A. awamori</i>	61.3	--	--
rCBHI wt genomic (G)	<i>A. awamori</i>	63.3	--	--
rCBHI N45A	<i>A. awamori</i>	58.3	--	--
rCBHI N270/45A	<i>A. awamori</i>	58.3	--	--
rCBHI N384/270A	<i>A. awamori</i>	58.8		

As shown in Table 1, Western blot analysis of the supernatant, obtained from a single glycosylation site mutant CBHIN270A culture expressed in *A. awamori*, demonstrated that a decrease, to lower molecular weight (61.7 kDa), in the amount of glycosylation of the protein had occurred, as compared to that in the wild type cDNA (63.3 kDa), and the wild type genomic DNA (63.3 kDa). These results demonstrate a reduction in the level of glycosylation in the reduced glycosylation mutant CBHIN270A, via expression in *A. awamori*. It is also shown, in the Table, that the CBHIN270A enzyme nearly retained its native enzymatic activity when assayed using the pNPL substrate. The variants CBHIN45A and CBHI384A also demonstrate a reduction in amount of glycosylation and native activity when expressed from the heterologous host *A. awamori* and when combined in the double mutations CBHIN270/45A and CBHIN270/384A reduce the level of glycosylation further.

#### **Example 5. Amino Acid Mutations Targeted To Improve Thermal Tolerance Of CBH I Helix Capping Mutants.**

All  $\alpha$ -helices display dipole moments, i.e. positive at N-terminal and negative at C-terminal. Compensation for such dipole moments (capping) has been observed in a number of protein structures<sup>1, 2</sup> and has been shown to improve the protein stability. For example, the introduction of a negatively charged amino acid at the N-terminus and a positively charged amino acid at C-terminus of an  $\alpha$ -helix increased the thermostability of T4 lysozyme<sup>3</sup> and hen

lysozyme<sup>4</sup>, via an electrostatic interaction with the "helix dipole." Five amino acid sites were identified for helix capping (see Table 5).

#### **Peptide Strain Removal Mutants.**

A small fraction of residues adopt torsion angles, phi-psi angles, which are unfavorable. It has been shown that mutation of such residues to Gly increased the protein stability as much as 4 kcal/mol. One amino acid site was selected for peptide strain removal (see Table 3).

#### **Helix Propensity Mutants.**

Two amino acid sites were selected for helix propensity improvement.

#### **Disulfide Bridge Mutants.**

Disulfide bonds introduced between amino acid positions 9 and 164 and between 21 and 142 in phage T4 lysozyme have been shown to significantly increase the stability of the respective enzymes toward thermal denaturation. The engineered disulfide bridge between residues 197 and 370 of CBH I should span the active site cleft and enhance its thermostability. The active site of CBH I is in a tunnel. The roof over the tunnel appears to be fairly mobile (high temperature-factors). At an elevated temperature the mobility of the tunnel is too significant to position all the active site residues. The disulfide linkage should stabilize the roof of the tunnel making the enzyme a consistent exocellulase even at a high temperature. Two amino acid sites were identified for new disulfide bridge generation.

#### **Deletion Mutants.**

Thermostable proteins have shorter loops that connect their structural elements than typical proteins. Our sequence alignment of CBH I, with its close homologs, suggests that the following residues may be deleted without significantly affecting its function. These loops exhibited high mobility as well. Three loops were identified, but these modifications were considered high risk (buried hydrophobic regions may be exposed to solvent upon deletion of a natural loop) and will be saved for future work.

#### **Proline Replacement Mutants.**

The unique structure of proline dictates that fewer degrees of freedom are allowed around the alpha carbon than most other amino acids. The result of this structure is that peptides tend to

loose flexibility in regions rich with proline. In order to assess possible sites for replacement of existing amino acids with proline, the phi/psi angles of candidate amino acid sites must conform with those consistent with proline. Each new site must also be evaluated for allowable side chain interactions and assurance that interactions with substrate are not altered. Seventeen amino acid sites were identified for proline replacement (See Table 2).

**Example 6. Nucleic acid sequence of a variant exoglucanase.**

The present example demonstrates the utility of the present invention for providing a nucleic acid molecule having a nucleic acid sequence that has a sequence 5'-GGCGGAAACCCGCCTGGCACCACC-3' (SEQ ID NO: 3). The identified nucleic acid sequence presents a novel linker region nucleic acid sequence that differs from previously reported nucleic acid sequence by the addition of one (1) codon, and the alteration of an adjacent codon, both encoding a proline (See Figure 4). The invention in some aspects thus provides a nucleic acid molecule encoding a cellobiohydrolase having a nucleic acid sequence that comprises a linker region of about 20 to 60 nucleotides 6 to 20 amino acids in length as identified here.

Table 2. Proline mutations to improve thermal tolerance.

Mutation	Native sequence and mutagenic oligonucleotide
SEQ ID NO: 10 <i>S8P - native sense strand</i>	5'-GCACTCTCCAATCGGAGACTCACCCG-3'
SEQ ID NO: 11 Mutagenic sense strand	5'-GCACTCTCCAAC <u>CG</u> GAGACTCACCCG-3'
SEQ ID NO: 12 Mutagenic anti-sense strand	5'-CGGGTGAGTCTCC <u>GG</u> TGGAGAGTGC-3'
SEQ ID NO: 13 <i>N27P - native sense strand</i>	5'-GGCACGTGCACTCAACAGACAGGCTCCG-3'
SEQ ID NO: 14 Mutagenic sense strand	5'-GGCACGTGCACTCC <u>AC</u> AGACAGGCTCCG-3'
SEQ ID NO: 15 Mutagenic anti-sense strand	5'-CGGAGCCTGTCTGT <u>GG</u> AGTGACGTGCC-3'
SEQ ID NO: 16 <i>A43P - native sense strand</i>	5'-GGCGCTGGACTCACGCTACGAACAGCAGCACG-3'
SEQ ID NO: 17 Mutagenic sense strand	5'-GGCGCTGGACTCAC <u>CT</u> ACGAACAGCAGCACG-3'
SEQ ID NO: 18 Mutagenic anti-sense strand	5'-CGTGCTGCTGTTCTAG <u>GG</u> TGAGTCCAGCGCC-3'

# Appendix B

Patent  
Attorney Docket # NREL 99-45

SEQ ID NO: 19 <i>G75P - native sense strand</i>	5'-GCTGTCTGGACGGTGCCGCCTACGCG-3'
SEQ ID NO: 20 Mutagenic sense strand	5'-GCTGTCTGGAC <u>CC</u> TGCCGCCTACGCG-3'
SEQ ID NO: 21 Mutagenic anti-sense strand	5'-CGCGTAGGCGGCAGGGTCCAGACAGC-3'
SEQ ID NO: 22 <i>G94P - native sense strand</i>	5'-GCCTCTCCATTGGCTTTGTACCCC-3'
SEQ ID NO: 23 Mutagenic sense strand	5'-GCCTCTCCATT <u>CC</u> CTTTGTACCCC-3'
SEQ ID NO: 24 Mutagenic anti-sense strand	5'-GGGTGACAAAGGGAATGGAGAGGC-3'
SEQ ID NO: 25 <i>E190P - native sense strand</i>	5'-GGCCAACGTTGAGGGCTGGGAGCC-3'
SEQ ID NO: 26 Mutagenic sense strand	5'-GGCCAACGTT <u>CC</u> GGGCTGGGAGCC-3'
SEQ ID NO: 27 Mutagenic anti-sense strand	5'-GGCTCCCAGCCC <u>GA</u> ACGTTGGCC-3'
SEQ ID NO: 28 <i>S195P - native sense strand</i>	5'-GGCTGGGAGCCGTCATCCAACAACGCG-3'
SEQ ID NO: 29 Mutagenic sense strand	5'-GGCTGGGAGCCG <u>C</u> ATCCAACAACGCG-3'
SEQ ID NO: 30 Mutagenic anti-sense strand	5'-CGCGTTGTTGGATGGCGGCTCCCAGCC-3'
SEQ ID NO: 31 <i>K287P - native sense strand</i>	5'-CGATACCACCAAGAAATTGACCGTTGTACCCC-3'
SEQ ID NO: 32 Mutagenic sense strand	5'-CGATACCACCAAG <u>CC</u> ATTGACCGTTGTACCCC-3'
SEQ ID NO: 33 Mutagenic anti-sense strand	5'-GGGTGACAACGGTCAAT <u>TGG</u> CTGGTGGTATCG-3'
SEQ ID NO: 34 <i>A299P - native sense strand</i>	5'-CGAGACGTCGGGTGCCATCAACCGATAC-3'
SEQ ID NO: 35 Mutagenic sense strand	5'-CGAGACGTCGGGT <u>CC</u> CATCAACCGATAC-3'
SEQ ID NO: 36 Mutagenic anti-sense strand	5'-GTATCGGTTGATGGGACCCGACGTCTCG-3'
SEQ ID NO: 37 <i>Q312P/N315P - native sense strand</i>	5'-GGCGTCACTTTCCAGCAGCCCAACGCCGAGCTTGG-3'
SEQ ID NO: 38 Mutagenic sense strand	5'-GGCGTCACTTTCC <u>CG</u> CAGCCCC <u>CC</u> CGCCGAGCTTGG-3'
SEQ ID NO: 39	5'-CCAAGCTCGGCGGGGGGCTGCGGGAAAGTGACGCC-3'

Mutagenic anti-sense strand	
SEQ ID NO: 40 <i>G359P - native sense strand</i>	5'-GGCTACCTCTGGCGGCATGGTTCTGG-3'
SEQ ID NO: 41 Mutagenic sense strand	5'-GGCTACCTCT <u>CCC</u> GGCATGGTTCTGG-3'
SEQ ID NO: 42 Mutagenic anti-sense strand	5'-CCAGAACCATGCCG <u>GG</u> AGAGGTAGCC-3'
SEQ ID NO: 43 <i>S398P/S401 P- native sense strand</i>	5'-GCGGAAGCTGCTCCACCAGCTCCGGTGTCCCTGC-3'
SEQ ID NO: 44 Mutagenic sense strand	5'-GCGGAAGCTGCC <u>CC</u> ACCAGC <u>CC</u> GGTGTCCCTGC-3'
SEQ ID NO: 45 Mutagenic anti-sense strand	5'-GCAGGGACACCG <u>GGG</u> GCTGGTGG <u>GC</u> CAGCTTCCGC-3'
SEQ ID NO: 46 <i>A414P - native sense strand</i>	5'-GTCTCCCAACGCCAAGGTCACC-3'
SEQ ID NO: 47 Mutagenic sense strand	5'-GTCTCCCAAC <u>CC</u> CAAGGTCACC-3'
SEQ ID NO: 48 Mutagenic anti-sense strand	5'-GGTGACCTTGG <u>GG</u> TTGGGAGAC-3'
SEQ ID NO: 49 <i>N431P/S433P - native sense strand</i>	5'-GGCAGCACCGGCAACCCTAGCGGCGGCAACCC-3'
SEQ ID NO: 50 Mutagenic sense strand	5'-GGCAGCACCGGC <u>CCC</u> CCT <u>CC</u> CGGCGGCAACCC-3'
SEQ ID NO: 51 Mutagenic anti-sense strand	5'-GGGTTGCCGCCG <u>GGG</u> AGG <u>GGG</u> CCCGGTGCTGCC-3'

Table 3. Mutation to remove peptide strain.

Mutation site	Native sequence and mutagenic oligonucleotide
SEQ ID NO: 52 <i>S99G- native sense strand</i>	5'-GGCTTTGTCACCCAGTCTGCGCAGAAGAACGTTGGC-3'
SEQ ID NO: 53 Mutagenic sense strand	5'-GGCTTTGTCACCCAG <u>GCT</u> GCGCAGAAGAACGTTGGC-3'
SEQ ID NO: 54 Mutagenic anti-sense strand	5'-GCCAACGTTCTTCTGCGC <u>ACC</u> CTGGGTGACAAAGCC-3'

Table 3b. Y245G analogs to remove product inhibition.

Mutation site	Native sequence and mutagenic oligonucleotide
SEQ ID NO: 55 <i>R251A - native sense strand</i>	5'-CCGATAACAGATATGGCGGC-3'
SEQ ID NO: 56 Mutagenic sense strand	5'-CCGATAAC <u>GC</u> CTATGGCGGC-3'
SEQ ID NO: 57	5'-GCCGCCATAG <u>GCG</u> TTATCGG-3'

# Appendix B

Patent  
Attorney Docket # NREL 99-45

Mutagenic anti-sense strand	
SEQ ID NO: 58 <i>R394A- native sense strand</i>	5'-CCCGGTGCCGTGCGCGGAAGCTGCTCCACC-3'
SEQ ID NO: 59 Mutagenic sense strand	5'-CCCGGTGCCGTG <u>GCC</u> GGAAGCTGCTCCACC-3'
SEQ ID NO: 60 Mutagenic anti-sense strand	5'-GGTGGAGCAGCTTCCG <u>GCC</u> ACGGCACCGGG-3'
SEQ ID NO: 61 <i>F338A- native sense strand</i>	5'-GCTGAGGAGGCAGAATTTCGGCGGATCCTCTTTCTC-3'
SEQ ID NO: 62 Mutagenic sense strand	5'-GCTGAGGAGGCAGAA <u>GCC</u> GCGGATCCTCTTTCTC-3'
SEQ ID NO: 63 Mutagenic anti-sense strand	5'-GAGAAAGAGGATCCGCC <u>GGC</u> TTCTGCCTCCTCAGC-3'
SEQ ID NO: 64 <i>R267A- native sense strand</i>	5'-GGAACCCATACCGCCTGGGCAACACCAGC-3'
SEQ ID NO: 65 Mutagenic sense strand	5'-GGAACCCATAC <u>GCC</u> CTGGGCAACACCAGC-3'
SEQ ID NO: 66 Mutagenic anti-sense strand	5'-GCTGGTGTGCCCAGG <u>GCG</u> TATGGGTTC-3'
SEQ ID NO: 67 <i>E385A- native sense strand</i>	5'-CCTACCCGACAAACGAGACCTCCTCCACACCCGG-3'
SEQ ID NO: 68 Mutagenic sense strand	5'-CCTACCCGACAAAC <u>GCC</u> ACCTCCTCCACACCCGG-3'
SEQ ID NO: 69 Mutagenic anti-sense strand	5'-CCGGGTGTGGAGGAGGT <u>GCG</u> TTTGTGGGTAGG-3'

Table 4. N to A mutations to remove glycosylation.

Mutant	Native sequence and mutagenic oligonucleotide
SEQ ID NO: 70 <i>N45A - native sense strand</i>	5'-GGACTCACGCTACGAACAGCAGCACGAACTGC-3'
SEQ ID NO: 71 Mutagenic sense strand	5'-GGACTCACGCTACGGCCAGCAGCACGAACTGC-3'
SEQ ID NO: 72 Mutagenic anti-sense strand	5'-GCAGTTCGTGCTGCTGGCCGTAGCGTGAGTCC-3'
SEQ ID NO: 73 <i>N270A - native sense strand</i>	5'-CCCATACCGCCTGGGCAACACCAGCTTCTACGGCCCC-3'
SEQ ID NO: 74 Mutagenic sense strand	5'-CCCATACCGCCTGGGCGCCACCAGCTTCTACGGCCCC-3'
SEQ ID NO: 75 Mutagenic anti-sense strand	5'-GGGCCGTAGAAGCTGGTGCCGCCCAGGCGGTATGGG-3'
SEQ ID NO: 76 <i>N384A - native sense strand</i>	5'-GGACTCCACCTACCCGACAAACGAGACCTCCTCCACACCCG-3'
SEQ ID NO: 77 Mutagenic sense strand	5'-GGACTCCACCTACCCGACAGCCGAGACCTCCTCCACACCCG-3'
SEQ ID NO: 78 Mutagenic anti-sense strand	5'-CGGGTGTGGAGGAGGTCTCGGCTGTCTGGGTAGGTGGAGTCC-3'

Table 5. Helix capping mutations to improve thermal tolerance.

Mutant	Native sequence and mutagenic oligonucleotide
SEQ ID NO: 79 <i>E337R - native sense strand</i>	5'-GCTGAGGAGGCAGAATTCGGCGG-3'
SEQ ID NO: 80 Mutagenic sense strand	5'-GCTGAGGAGGCACGCTTCGGCGG-3'
SEQ ID NO: 81 Mutagenic anti-sense strand	5'-CCGCCGAAGCCGTGCCTCCTCAGC-3'
SEQ ID NO: 82 <i>N327D - native sense strand</i>	5'-GGCAACGAGCTCAACGATGATTACTGC-3'
SEQ ID NO: 83 Mutagenic sense strand	5'-GGCAACGAGCTCGACGATGATTACTGC-3'
SEQ ID NO: 84 Mutagenic anti-sense strand	5'-GCAGTAATCATCGTCGAGCTCGTTGCC-3'
SEQ ID NO: 85 <i>A405D - native sense strand</i>	5'-CCGGTGTCCCTGCTCAGGTCGAATCTCAGTCTCCC-3'
SEQ ID NO: 86 Mutagenic sense strand	5'-CCGGTGTCCCTGATCAGGTCGAATCTCAGTCTCCC-3'
SEQ ID NO: 87 Mutagenic anti-sense strand	5'-GGGAGACTGAGATTGACCTGATCAGGGACACCGG-3'

# Appendix B

Patent  
Attorney Docket # NREL 99-45

SEQ ID NO: 88 <i>Q410R Q410R - native sense strand</i>	5'-GCTCAGGTCGAATCT <b>CAGT</b> CTCCCAACGCC-3'
SEQ ID NO: 89 Mutagenic sense strand	5'-GCTCAGGTCGAATCT <b><u>CG</u></b> CTCTCCCAACGCC-3'
SEQ ID NO: 90 Mutagenic anti-sense strand	5'-GGCGTTGGGAGAG <b><u>GCG</u></b> GAGATTCGACCTGAGC-3'
SEQ ID NO: 91 <i>N64D - native sense strand</i>	5'-CCCTATGTCCTGACA <b>AC</b> GAGACCTGCGCG-3'
SEQ ID NO: 92 Mutagenic sense strand	5'-CCCTATGTCCTGAC <b><u>GAC</u></b> GAGACCTGCGCG-3'
SEQ ID NO: 93 Mutagenic anti-sense strand	5'-CGCGCAGGTCT <b><u>CGT</u></b> CGTCAGGACATAGGG-3'
SEQ ID NO: 94 <i>N64D - native sense strand</i>	5'-GCTCGACCCTATGTCCTGACA <b>AC</b> GAGACCTGCGCGAAGAACTGC-3'
SEQ ID NO: 95 Mutagenic sense strand	5'-GCTCGACCCTATGTCCTGAC <b><u>GAC</u></b> GAGACCTGCGCGAAGAACTGC-3'
SEQ ID NO: 96 Mutagenic anti-sense strand	5'-GCAGTTCTTCGCGCAGGTCT <b><u>CGT</u></b> CGTCAGGACATAGGGTCGAGC-3'

Legend for Tables 2, 3, 3b, 4 and 5. Amino acid mutations sites are listed in the left column. The first letter in the designation is the amino acid of the native protein based upon IUPAC convention for one-letter codes for amino acids. The number represents the amino acid location as designated from the start of the mature protein (excluding the signal peptide, i.e. QSA...). The letter designation after the number represents the amino acid that will occur as a result of the mutation. For example N64D represents the asparagine at site 64 changed to an aspartic acid. The native sense strand sequence for each site is listed in the right column with the oligonucleotide primers (sense and anti-sense) used to obtain the desired mutation below the native sequence in each case. In addition the codon for the targeted amino acid is bolded and the nucleotide substitutions in the mutagenic primers underlined. In some cases only one nucleotide substitution was required to make the desired change, and in others 2 or 3 substitutions were required. In a few cases, double mutations were made with a single mutagenic oligonucleotide.

**Bibliography**

The following references are specifically incorporated herein by reference.

Fagertein et. Al. 1984. FEBS. 1265, 167 (2): 389-315.

von Ossowski, I., Teeri, T., Kalkkinen, N., and Oker-Blom, C., **Biochem. Biophysical Comm.**, 233, 25-29 (1997).

Laymon, R.A., Adney, W.S., Mohagheghi, A., Himmel, M.E., and Thomas, S.R. **Appl. Biochem. Biotechnol.**, 57/58, 389-400 (1996).

Teeri, T. T., (1987) Doctoral Thesis, VTT Publications No. 38.

Reinikainen, T., Rouhonen, L., Nevanen, T., Laaksonen, L., Kraulis, P., Jones, T.A., Knowles, J., and Teeri, T. **Proteins, Structure Function Genetics** 14, 475-482 (1992).

Penttila, M.E., Andre, L., Lehtovaara, P., Bailey, M., Teeri, T.T., Knowles, J.K.C. **Gene** 63, 103-112(1988).

Zurbriggen, B., Bailey, M.J., Penttila, M.E., Poutanen, K., and Linko, M. **J. Biotechnol.** 13, 267-278(1990).

Okada, H., Sekiya, T., Yokoyama, K., Tohda, H., Kumagai, H., and Morikawa, Y., **Appl. Microbiol. Biotechnol.**, 49, 301-308 (1998).

Maras, M., De Bruyn, A., Schraml, J., Herdewijn, P., Claeysens, M., Fiers, W., and Contreras, R., **Eur. J., Biochem.**, 245, 617-625 (1997).  
**Circular Dichroism of Proteins**

BoXu, Y., and Qing, S.Y. (1997) **J. Protein Chem.** 16, 107-111.

Lassig, F., Schultz, M. D., Gooch, M., Evans, B.R., and Woodward, J. (1995) **Arch. Biochem. Biophys.** 322, 119-126.

Penttila, M.E., Andre, L., Lehtovaara, P., Bailey, M., Teeri, T. T., and Knowles, J.K.C. (1988) **Gene** 63, 103-112.

Shoemaker, S.P. (1984), In 'The cellulase system of *Trichoderma reesei* : *Trichoderma* strain improvement and expression of *Trichoderma* cellulases in yeast' pp 593-600.

Van Arsdell, J.N., Kwok, S., Schweickart, V.L., Gelfand, D.H., and Innis, M. a. (1987) **Bio/Technology** 5, 60-64.

Richardson, J.S. & Richardson, D.C. Amino acid preferences for specific locations at the ends of alpha helices [published erratum appears in Science 1988 Dec 23;242(4886):1624]. **Science** 240, 1648-1652 (1988).

Presta, L.G. & Rose, G.D. Helix signals in proteins. **Science** 240, 1632-1641 (1988).

Nicholson, H., Anderson, D.E., Dao-pin, S. & Matthews, B.W. Analysis of the interaction between charged side chains and the alpha-helix dipole using designed thermostable mutants of phage T4 lysozyme. **Biochemistry** 30, 9816-9828 (1991).

Motoshima, H. et al. Analysis of the stabilization of hen lysozyme by helix macrodipole and charged side chain interaction. **J. Biochem.** (Tokyo) 121, 1076-1081 (1997).

Stites, W.E., Meeker, A.K. & Shortle, D. Evidence for strained interactions between side-chains and the polypeptide backbone. **J. Mol. Biol.** 235, 27-32 (1994).

Jacobson, R.H., Matsumura, M., Faber, H.R. & Matthews, B.W. Structure of a stabilizing disulfide bridge mutant that closes the active-site cleft of T4 lysozyme. **Protein Science** 1, 46-57 (1992).

Pjura, P.E., Matsumura, M., Wozniak, J.A. & Matthews, B.W. Structure of a thermostable disulfide-bridge mutant of phage T4 lysozyme shows that an engineered cross-link in a flexible region does not increase the rigidity of the folded protein. **Biochemistry** 29, 2592-2598 (1990).  
Sakon, J., Adney, W.S., Himmel, M.E., Thomas, S.R. & Karplus, P.A. Crystal structure of thermostable family 5 endocellulase E1 from *Acidothermus cellulolyticus* in complex with cellotetraose. **Biochemistry** 35, 10648-10660 (1996).

Russell, R.J.M., Hough, D.W., Danson, M.J. & Taylor, G.L. The crystal structure of citrate synthase from the thermophilic Archaeon, *Thermoplasma acidophilum*. **Structure** 2, 1157-1167 (1994).

Modeling and measurements of fungal growth and morphology in submerged fermentations. Cui, YQ; Okkerse, WJ; vanderLans, RGJM; Luyben, KCAM. **Biotechnol. Bioeng.** October 20, 1998 v60 i2 p216-229 (14).

*Agrobacterium tumefaciens*-mediated transformation of filamentous fungi. deGroot, MJA; Bundock, P; Hooykaas, PJJ; Beijersbergen, AGM. **Nature Biotechnol.** September 1998 v16 i9 p839-842 (4).

Effect on thermostability and catalytic activity of introducing disulfide bonds into *Aspergillus awamori* glucoamylase. Li, YX; Coutinho, PM; Ford, C. **Protein Eng.** August 1998 v11 i8 p661-667 (7).

Expression and secretion of defined cutinase variants by *Aspergillus awamori*. VanGemeran, IA; Beijersbergen, A; van den Hondel, CAMJJ; Verrips, CT. **Appl. Environ. Microbiol.** August 1998 v64 i8 p2794-2799 (6).

Aspects of the use of complex media for submerged fermentation of *Aspergillus awamori*. Cui, YQ; Ouwehand, JNW; vanderLans, RGJM; Giuseppin, MLF; Luyben, KCAM. **Enzyme Microbial Technol.** July-August 1998 v23 i1-2 p168-177 (10).

Influence of fermentation conditions and scale on the submerged fermentation of *Aspergillus awamori*. Cui, YQ; vanderLans, RGJM; Giuseppin, MLF; Luyben, KCAM. **Enzyme Microb. Technol.** July-August 1998 v23 i1-2 p157-167 (11).

Intrinsic kinetic parameters of the pellet forming fungus *Aspergillus awamori*. Hellendöom, L; Mulder, H; van den Heuvel, JC; Ottengraf, SPP. **Biotechnol. Bioeng.** June 5, 1998 v58 i5 p478-485 (8).

Protein engineering of *Aspergillus awamori* glucoamylase to increase its pH optimum. Fang, TY; Ford, C. **Protein Eng.** May 1998 v11 i5 p383-388 (6).

Extracellular proteolytic processing of *Aspergillus awamori* GAI into GAI is supported by physico-chemical evidence. Nascimento, HJ; Soares, VF; Bon, EPS; Silva, JG. **Appl. Biochem. Biotechnol.** Spring 1998 v70-2 p641-650 (10).

Production of xylanase by *Aspergillus awamori* on synthetic medium in shake flask cultures. Siedenberg, D; Gerlach, SR; Schugerl, K; Giuseppin, MLF; Hunik, J. **Process Biochem.** March 1998 v33 i4 p429-433 (5).

Influence of morphology on product formation in *Aspergillus awamori* during submerged fermentations. Johansen, CL; Coolen, L; Hunik, JH. **Biotechnol. Progress.** March-April 1998 v14 i2 p233-240 (8).

Effects of dissolved oxygen tension and mechanical forces on fungal morphology in submerged fermentation. Cui, YQ; vander Lans, RGJM; Luyben, KCAM. **Biotech. Bioeng.** February 20, 1998 v57 i4 p409-419 (11).

Effect of introducing proline residues on the stability of *Aspergillus awamori*. Li, YX; Reilly, PJ; Ford, C. **Protein Eng.** October 1997 v10 i10 p1199-1204 (6).

The ER chaperone encoding bipA gene of black *Aspergilli* is induced by heat shock and unfolded proteins. vanGemeren, IA; Punt, PJ; DrintKuyvenhoven, A; Broekhuijsen, MP; vanHoog, A; Beijersbergen, A; Verrips, CT; van den Hondel, CAMJJ. **Gene.** October 1, 1997 v198 i1-2 p43-52 (10).

Effect of agitation intensities on fungal morphology of submerged fermentation. Cui, YQ; vanderLans, RGJM; Luyben, KCAM. **Biotech. Bioeng.** September 5, 1997 v55 i5 p715-726 (12).

Characterization of the bip gene of *Aspergillus awamori* encoding a protein with an HDEL retention signal homologous to the mammalian BiP involved in polypeptide secretion. Hijarrubia, MJ; Casqueiro, J; Gutierrez, S; Fernandez, FJ; Martin, JF. **Current Genetics.** August 1997 v32 i2 p139-146 (8).

Expression and functional analysis of a hyperglycosylated glucoamylase in a parental host, *Aspergillus awamori* var. *kawachi*. Goto, M; Ekino, K; Furukawa, K. **Appl. Environ. Microbiol.** July 1997 v63 i7 p2940-2943 (4).

Glucoamylase gene fusions alleviate limitations for protein production in *Aspergillus awamori* at the transcriptional and (post)translational levels. Gouka, RJ; Punt, PJ; van den Hondel, CAMJJ. **Appl. Environ. Microbiol.** February 1997 v63 i2 p488-497 (10).

Kinetics of mRNA and protein synthesis of genes controlled by the 1,4-beta-endoxylanase A promoter in controlled fermentations of *Aspergillus awamori*. Gouka, RJ; Stam, H; Fellingner, AJ; Muijsenberg, RJGT; vandeWijngaard, AJ; Punt, PJ; Musters, W; van den Hondel, CAMJJ. **Appl. Environ. Microbiol.** October 1996 v62 i10 p3646-3649 (4).

An expression system based on the promoter region of the *Aspergillus awamori* 1,4-beta-endoxylanase A gene. Gouka, RJ; Hessing, JGM; Punt, PJ; Stam, H; Musters, W; van den Hondel, CAMJJ. **Appl. Microbiol. Biotechnol.** (1996) v46 i1 p28-35 (8).

The effect of pre- and pro-sequences and multicopy integration on heterologous expression of the *Fusarium solani* pisi cutinase gene in *Aspergillus awamori*. vanGemeran, IA; Beijersbergen, A; Musters, W; Gouka, RJ; vandenHondel, CAMJJ; Verrips, CT. **Appl. Microbiol. Biotechnol.** (1996) v45 i6 p755-763 (9).

Analysis of heterologous protein production in defined recombinant *Aspergillus awamori* strains. Gouka, RJ; Punt, PJ; Hessing, JGM; van den Hondel, CAMJJ. **Appl. Environ. Microbiol.** (1996) v62 i6 p1951-1957 (7).

Effect of replacing helical glycine residues with alanines on reversible and irreversible stability and production of *Aspergillus awamori* glucoamylase. Chen, HM; Li, YX; Panda, T; Buehler, F; Ford, C; Reilly, PJ. **Protein Eng.** (1996) v9 i6 p499-505.

**Claims**

1 through 5. (Cancelled)

6. (Previously presented) A nucleic acid molecule having a nucleic acid sequence encoding a variant cellobiohydrolase that is mutated with respect to a wild-type cellobiohydrolase of SEQ ID NO: 5, the mutation providing means for improving functionality of the variant cellobiohydrolase with respect to the wild-type cellobiohydrolase.

7. (Currently amended) The nucleic acid molecule of claim 6 wherein the means for improving is selected from the group consisting of:

- (a) proline substituted at a position selected from the group consisting of position 8, 27, 43, 75, 94, 190, 195, 287, 299, 312, 315, 359, 398, 401, 414, 431, 433, and any combination thereof;
- (b) a helix-capping mutation defined as an arginine or aspartic acid residue is substituted at a position selected from the group consisting of position 64, 337, 327, 405, 410 and any combination thereof;
- (c) substitution of glycine at position 99;
- ~~(d) a deletion from the group consisting of position 99-101, position 278-279, and position 387, and any combination thereof;~~
- ~~(d)(e)~~ [a]substitution of cysteine at positions 197 and 370;
- ~~(e)(f)~~ substitution of a non-glycosyl accepting amino acid residue in place of an N-glycosylation site amino acid residue at a position selected from the group consisting of position 45, 270, 384 and any combination thereof,
- ~~(f)(g)~~ alanine substitution at a position selected from the group consisting of position 45, 270, 384 and any combination thereof; and
- ~~(h) alanine at a position selected from the group consisting of position 252, 294, 338, 267, 385, and any combination thereof; and~~

(g)(i) any combination of the mutations of (a), (b), (c), (d), (e), (f), ~~(g)~~, ~~(h)~~, wherein the positional reference is within ~~an~~ the amino acid sequence of the wild-type encoding a native cellobiohydrolase [I] of SEQ ID NO: 5.

8. (Previously presented) The nucleic acid molecule of claim 7 wherein the means for improving comprises the proline substituted at a position selected from the group consisting of position 8, 27, 43, 75, 94, 190, 195, 287, 299, 312, 315, 359, 398, 401, 414, 431, 433, and any combination thereof.

9. (Previously presented) The nucleic acid molecule of claim 7 wherein the means for improving comprises the helix-capping mutation defined as an arginine or aspartic acid residue is substituted at a position selected from the group consisting of position 64, 337, 327, 405, 410 and any combination thereof.

10. (Currently amended) The nucleic acid molecule of claim 7 wherein the means for improving comprises substitution of the glycine at position 99.

11. (Currently amended) A method for mutating a nucleic acid encoding a wild type cellobiohydrolase of SEQ ID NO: 5, the method comprising:

mutating the wild type cellobiohydrolase with a mutation selected from the group consisting of:

- (a) proline substituted at a position selected from the group consisting of position 8, 27, 43, 75, 94, 190, 195, 287, 299, 312, 315, 359, 398, 401, 414, 431, 433, and any combination thereof;
- (b) a helix-capping mutation defined as an arginine or aspartic acid residue is substituted at a position selected from the group consisting of position 64, 337, 327, 405, 410 and any combination thereof;
- (c) substitution of glycine at position 99;
- (d) ~~a deletion from the group consisting of position 99-101, position 278-279, and position 387, and any combination thereof;~~

- (d)(e) [a]substitution of cysteine at positions 197 and 370;
- (e)(f) substitution of a non-glycosyl accepting amino acid residue in place of an N-glycosylation site amino acid residue at a position selected from the group consisting of position 45, 270, 384 and any combination thereof,
- (f)(g) alanine substitution at a position selected from the group consisting of position 45, 270, 384 and any combination thereof; and
- (h) ~~alanine at a position selected from the group consisting of position 252, 294, 338, 267, 385, and any combination thereof; and~~
- (g)(i) any combination of the mutations of (a), (b), (c), (d), (e), (f), ~~(g)~~, ~~(h)~~, wherein the positional reference is within ~~an~~ the amino acid sequence of the wild-type encoding a native cellobiohydrolase [I ] of SEQ ID NO: 5.

12. (Currently amended) The method of claim 11, wherein the mutation comprises substitution of a ~~the~~ non-glycosyl accepting amino acid residue in place of an N-glycosylation site amino acid residue at a position selected from the group consisting of position 45, 270, 384 and any combination thereof.

13. (Previously presented) The method of claims 11, wherein the step of mutating comprises site-directed mutagenesis.

14. (Currently amended) The method of claim 11, further comprising a step of shortening a linker region of the wild-type cellobiohydrolase sequence being shortened with respect to wild-type linker region SEQ ID NO: 2 to provide ~~comprises~~ a linker region ~~sequence~~ having a length of from about 6 amino acids ~~20 nucleotides~~ to about 17 amino acids ~~50 nucleotides~~ located, between a catalytic domain and a cellulose binding domain (CBD) of SEQ ID NO: 5.

15. (Currently amended) An exoglucanase, comprising the sequence change encoded by SEQ ID NO: 71~~20~~.

16. (Currently amended) An exoglucanase, comprising the sequence change encoded by SEQ ID NO: 74~~21~~.

17. (Cancelled).
18. (Cancelled).
19. (Cancelled).
20. (Currently amended) The nucleic acid molecule of claim 7 wherein the means for enhancing thermostability comprises substitution of a ~~the~~ cysteine at positions 197 and 370.
21. (Currently amended) The nucleic acid molecule of claim 7 wherein the means for enhancing thermostability comprises substitution of a ~~the~~ non-glycosyl accepting amino acid residue in place of an N-glycosylation site amino acid residue at a position selected from the group consisting of position 45, 270, 384 and any combination thereof.
22. (Currently amended) The nucleic acid molecule of claim 7 wherein the means for enhancing thermostability comprises substitution of an ~~the~~ alanine at a position selected from the group consisting of position 45, 270, 384 and any combination thereof.
23. (Cancelled).
24. (Previously presented) The nucleic acid molecule of claim 7 wherein the means for improving comprises means for enhancing thermostability.
25. (Currently amended) The nucleic acid molecule of claim ~~1~~ 6, wherein the variant cellobiohydrolase comprises a linker region ~~sequence~~ having a length of from about 6 amino acids ~~20 nucleotides~~ to about 17 amino acids ~~50 nucleotides~~ located, between a catalytic domain and a cellulose binding domain (CBD), ~~the linker region sequence being shortened with respect to SEQ ID NO: 2.~~
26. (Currently amended) A nucleic acid molecule having a nucleic acid sequence encoding a variant cellobiohydrolase that is mutated with respect to a wild-type cellobiohydrolase of SEQ ID NO: 5, the mutation selected from the group consisting of:

## Appendix B

Patent  
Attorney Docket # NREL 99-45

- (a) proline substituted at a position selected from the group consisting of position 8, 27, 43, 75, 94, 190, 195, 287, 299, 312, 315, 359, 398, 401, 414, 431, 433, and any combination thereof;
  - (b) a helix-capping mutation defined as an arginine or aspartic acid residue is substituted at a position selected from the group consisting of position 64, 337, 327, 405, 410 and any combination thereof;
  - (c) substitution of glycine at position 99;
  - ~~(d) a deletion from the group consisting of position 99-101, position 278-279, and position 387, and any combination thereof;~~
  - ~~(d)(e)~~ [a]substitution of cysteine at positions 197 and 370;
  - ~~(e)(f)~~ substitution of a non-glycosyl accepting amino acid residue in place of an N-glycosylation site amino acid residue at a position selected from the group consisting of position 45, 270, 384 and any combination thereof,
  - ~~(f)(g)~~ alanine substitution at a position selected from the group consisting of position 45, 270, 384 and any combination thereof; and
  - ~~(h) alanine at a position selected from the group consisting of position 252, 294, 338, 267, 385, and any combination thereof; and~~
  - ~~(g)(i)~~ any combination of the mutations of (a), (b), (c), (d), (e), (f), ~~(g)~~, ~~(h)~~, wherein the positional reference is within an the amino acid sequence of the wild-type encoding a native cellobiohydrolase [I] of SEQ ID NO: 5.
27. (New) An exoglucanase, comprising the sequence change encoded by SEQ ID NO: 77.
28. (New) An exoglucanase composition, comprising a combination of exoglucanases selected from the group consisting of exoglucanases defined by claims 15, 16 and 27.



**ABSTRACT**

~~A nucleic acid molecule having a nucleic acid sequence that encodes a linker region of exoglucanase, said nucleic acid sequence comprising the nucleotide sequence 5'~~  
~~GGCGGAAACCCGCCTGGCACCACC 3' (SEQ ID NO: 3).~~The disclosure provides a method  
for preparing an active exoglucanase in a heterologous host of eukaryotic origin. The method  
includes mutagenesis to reduce glycosylation of the exoglucanase when expressed in a  
heterologous host. It is further disclosed a method to produce variant cellobiohydrolase that is  
stable at high temperature through mutagenesis.